Home › Funds › BAKER BROS. ADVISORS LP › KYMR

BAKER BROS. ADVISORS LP position in KYMR

KYMERA THERAPEUTICS INC · Health Care

BAKER BROS. ADVISORS LP reported holding 8,657,242 shares of KYMR (KYMERA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$992.7M, representing 5.19% of its reported portfolio and ranking #6 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed KYMR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)8.66M sh
Reported value held$992.73M
Portfolio Weight5.19%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's KYMR position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in KYMR in Q3 2023 at 4,750,400 shares (US$66.0M). The position peaked in Q2 2026 at 8,657,242 shares, worth US$992.7M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 8,657,242 shares valued at US$992.7M. Notable position changes include a 26% increase in Q4 2023 (shares rose 58% over the following quarter), a 30% increase in Q4 2025 (shares rose 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.75M $66.03M New
Q4 2023 6.00M $152.66M Add
Q1 2024 6.00M $241.04M Hold
Q2 2024 6.00M $178.98M Hold
Q3 2024 6.00M $283.79M Hold
Q4 2024 6.00M $241.22M Hold
Q1 2025 6.00M $164.11M Hold
Q2 2025 6.65M $290.27M Add
Q3 2025 6.65M $376.47M Hold
Q4 2025 8.66M $673.62M Add
Q1 2026 8.66M $721.06M Hold
Q2 2026 8.66M $992.73M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KYMR and 13F data

KYMR (KYMERA THERAPEUTICS INC) is a Health Care company. 57 other funds we track also report a position in KYMR — the largest reported positions include Avoro Capital Advisors LLC (US$857.1M), T. Rowe Price Investment Management, Inc. (US$717.5M), BVF INC/IL (US$444.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KYMR

All KYMR fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held KYMR?

BAKER BROS. ADVISORS LP has disclosed KYMR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in KYMR?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 8.66M shares of KYMR (KYMERA THERAPEUTICS INC), valued at $992.73M, representing 5.19% of its reported portfolio and ranking #6.

Has BAKER BROS. ADVISORS LP been buying or selling KYMR?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in KYMR. The position peaked in Q2 2026 at 8.66M shares.

Which other funds hold KYMR?

Other major institutional holders of KYMR include Avoro Capital Advisors LLC, T. Rowe Price Investment Management, Inc., BVF INC/IL, among 57 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.